We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Zoetis Inc. (NYSE:ZTS) is among the most undervalued stocks to invest in.
TheFly reported on May 27 that Argus downgraded ZTS from Buy to Hold following a sharp decline in the company’s share price, including a steep one-day drop of about 22% and continued subsequent weakness. The move reflects growing investor concern over the company’s near-term growth outlook and reduced confidence in its performance trajectory. The ****** yst noted that recent price action signals a shift in market sentiment, with pressure on the stock driven by deteriorating expectations rather than a single operational event.
In addition to that, earlier on May 7, Zoetis Inc. (NYSE:ZTS) released its financial results for the first quarter of 2026, reporting revenue of $2.3 billion, which reflected a 3% increase compared with the same period in 2025 and was flat on an organic operational basis. Net income totaled $601 million, or $1.42 per diluted share, showing stable performance on a reported basis with 6% per-share growth. Adjusted net income reached $646 million, or $1.53 per diluted share, representing 2% and 9% increases on a reported basis and 1% and 7% growth on an organic operational basis.
Goodluz/Shutterstock.com
The company noted a more challenging operating environment, including weaker veterinary visits and softer demand in companion animal products, alongside intensified competition. However, livestock and international segments delivered growth across cattle, poultry, swine, diagnostics, and parasiticides, partially offsetting U.S. declines and supporting overall portfolio resilience.
TheFly reported on May 27 that Argus downgraded ZTS from Buy to Hold following a sharp decline in the company’s share price, including a steep one-day drop of about 22% and continued subsequent weakness. The move reflects growing investor concern over the company’s near-term growth outlook and reduced confidence in its performance trajectory. The ****** yst noted that recent price action signals a shift in market sentiment, with pressure on the stock driven by deteriorating expectations rather than a single operational event.
In addition to that, earlier on May 7, Zoetis Inc. (NYSE:ZTS) released its financial results for the first quarter of 2026, reporting revenue of $2.3 billion, which reflected a 3% increase compared with the same period in 2025 and was flat on an organic operational basis. Net income totaled $601 million, or $1.42 per diluted share, showing stable performance on a reported basis with 6% per-share growth. Adjusted net income reached $646 million, or $1.53 per diluted share, representing 2% and 9% increases on a reported basis and 1% and 7% growth on an organic operational basis.
Goodluz/Shutterstock.com
The company noted a more challenging operating environment, including weaker veterinary visits and softer demand in companion animal products, alongside intensified competition. However, livestock and international segments delivered growth across cattle, poultry, swine, diagnostics, and parasiticides, partially offsetting U.S. declines and supporting overall portfolio resilience.
16 hours ago
